Skip to main content

Specific populations

Monoclonal antibody model

10-23-2023 | Type 1 diabetes | News

Teplizumab may PROTECT β-cell function in youth with newly diagnosed type 1 diabetes

Early treatment with the anti-CD3 monoclonal antibody teplizumab may help to preserve β-cell function in children and adolescents with newly diagnosed type 1 diabetes, results of the phase 3 PROTECT study show.

09-15-2023 | Type 2 diabetes | News

Young-onset type 2 diabetes diagnosis linked to shortened life expectancy

Younger age at type 2 diabetes diagnosis is associated with shorter life expectancy, with 3 to 4 years lost for every decade of earlier diagnosis.

06-02-2023 | Type 1 diabetes | News

Pregnancy-specific closed-loop system proves feasible for home use

Results of a pilot study show that a hybrid closed-loop insulin delivery system customized for pregnancy used by women with type 1 diabetes at home significantly improved their glucose outcomes.

05-12-2023 | Gestational diabetes | News

Early gestational diabetes intervention improves pregnancy outcomes

Identifying and treating women with gestational diabetes before 20 weeks’ gestation improves their pregnancy outcomes, shows the randomized TOBOGM trial.

Young latin woman pregnant measuring glucose at home (symbolic with model)

04-05-2023 | Gestational diabetes | News

Mild gestational glucose intolerance tied to future type 2 diabetes risk

Impaired glucose tolerance during pregnancy that does not meet the criteria for gestational diabetes nevertheless increases the likelihood that women will later develop type 2 diabetes, a study shows.

04-05-2023 | Flash glucose monitoring | News

Reduced acute complications for young people using CGM

Data from the DPV cohort show a reduced risk for severe hypoglycemia and diabetic ketoacidosis among children and young people with type 1 diabetes using continuous glucose monitoring rather than self-monitored blood glucose.

03-30-2023 | Artificial pancreas systems | News

Virtual closed-loop initiation success in very young children

The Tandem Control-IQ system delivers improved glucose control versus standard care in children with type 1 diabetes aged between 2 and 6 years and can be initiated virtually, report researchers.

03-21-2023 | Diabetes prevention | News

Verapamil promising for preserving beta-cell function in children

Two linked randomized trials published in JAMA support a role for verapamil, but not for intensive glycemic control, to slow C-peptide decline in children with newly diagnosed type 1 diabetes.